Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 12:11:1391-1400.
doi: 10.2147/CMAR.S190545. eCollection 2019.

The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy

Chaobin He  1 , Yu Zhang  2 , Zhiyuan Cai  1 , Xiaojun Lin  1
Affiliations

The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy

Chaobin He et al. Cancer Manag Res. .

Abstract

Purpose: This study was designed to evaluate the prognostic value of the combination of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) (neutrophil/platelet-to-lymphocyte ratio [NLR-PLR]) in patients with hepatocellular carcinoma (HCC) who receive transarterial chemoembolization (TACE) therapy.

Patients and methods: Data from 216 patients who were diagnosed with HCC after TACE therapy were retrospectively collected. R software was used to analyze the time-dependent receiver operating characteristic (ROC) curves and to compare the area under the ROC curves (AUROCs).

Results: The long-term survival rates were significantly higher for patients with lower values than those with higher values of NLR, PLR, and NLR-PLR. The mean overall survival decreased gradually with increases in the NLR-PLR score (P<0.0001). The AUROC values of the NLR-PLR score were consistently higher than those of NLR and PLR.

Conclusion: This study showed that the NLR-PLR score might be a useful predictor for patients with HCC who receive TACE therapy.

Keywords: hepatocellular carcinoma; neutrophil/platelet-to-lymphocyte ratio; transarterial chemoembolization.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Kaplan–Meier curves for OS in patients who were diagnosed with HCC after TACE therapy; patients were stratified according to the inflammation-based prognostic scores. Note: (A) NLR; (B) PLR; and (C) NLR–PLR. Abbreviations: HCC, hepatocellular carcinoma; NLR, neutrophil-to-lymphocyte ratio; NLR–PLR, neutrophil/platelet-to-lymphocyte ratio; OS, overall survival; PLR, platelet-to-lymphocyte ratio; TACE, transarterial chemoembolization.
Figure 2
Figure 2
Comparisons of the AUROC values for OS stratified by the inflammation-based prognostic scores at 1-year (A), 2-year (B), and 3-year (C). Abbreviations: AUROC, area under the ROC curves; NLR, neutrophil-to-lymphocyte ratio; NLR–PLR, neutrophil/platelet-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; OS, overall survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed
    1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255. - PubMed
    1. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(15):4115–4127. - PMC - PubMed
    1. Zhang J, Zhou ZG, Huang ZX, et al. Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chin J Cancer. 2016;35(1):25. - PMC - PubMed
    1. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236. - PubMed